Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 11/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855354 | 0.83 | XPO1 (0.46) | XPO1LMNAPOLB | |
| SCHEMBL27627602 | 0.79 | XPO1 (0.42) | XPO1HTT | |
| SCHEMBL855783 | 0.79 | LMNA (0.37) | XPO1CACNA1BCACNA1CCACNA1HCACNA1G | |
| SCHEMBL28503221 | 0.76 | XPO1 (0.40) | XPO1CACNA1BCACNA1CCACNA1HCACNA1G | |
| SCHEMBL2373934 | 0.75 | P2RX7 (0.43) | — | |
| SCHEMBL1592978 | 0.73 | XPO1 (0.53) | XPO1 | |
| SCHEMBL22028970 | 0.73 | XPO1 (0.49) | XPO1CACNA1BCACNA1CCACNA1HCACNA1G | |
| SCHEMBL22028997 | 0.73 | XPO1 (0.51) | XPO1CACNA1BCACNA1CCACNA1HLMNA | |
| SCHEMBL30592845 | 0.73 | XPO1 (0.51) | XPO1CACNA1BCACNA1CCACNA1HLMNA | |
| SCHEMBL22029019 | 0.72 | XPO1 (0.48) | XPO1CACNA1BCACNA1CCACNA1HCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2075249-B1 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| EP-1597250-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| EP-2075249-A2 | Indolylmaleimide derivatives | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060058356-A1 | Indolylmaleimide derivatives | NOVARTIS AG | 2006-03-16 | — | — | US | disclosed |
| EP-1597250-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004072062-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058356-A1 | Indolylmaleimide derivatives | GSK3B, GSK3A, GSKIP | XPO1 2257/4885CACNA1B 1226/4885CACNA1C 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.